The House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs.
A critical drug that has experienced shortages is Genzyme’s Fabrazyme (agalsidase beta), the only enzyme replacement therapy approved in the US for Fabry disease.
A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers
A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.